Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety

Matulonis U. A.; Penson R. T.; Domchek S. M.; Kaufman B.; Shapira-Frommer R.; Audeh M. W.; Kaye S.; Molife L. R.; Gelmon K. A.; Robertson J. D.; Mann H.; Ho T. W.; Coleman R. L.

首页> 外文期刊>Annals of oncology: official journal of the European Society for Medical Oncology >Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety

【24h】

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety

机译：Olaparib单药治疗晚期复发性卵巢癌和生殖系BRCA1 / 2突变的患者：疗效和安全性的多研究分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: The PARP inhibitor olaparib (Lynparza (TM)) demonstrates antitumor activity in women with relapsed ovarian cancer and a germline BRCA1/2 mutation (gBRCAm). Data from olaparib monotherapy trials were used to explore the treatment effect of olaparib in patients with gBRCAm ovarian cancer who had received multiple lines of prior chemotherapy.

机译：背景：PARP抑制剂olaparib（Lynparza（TM））在患有复发性卵巢癌和生殖系BRCA1 / 2突变（gBRCAm）的女性中表现出抗肿瘤活性。 olaparib单药治疗试验的数据用于探讨olaparib在已接受过多次化疗的gBRCAm卵巢癌患者中的治疗效果。

著录项

来源
《Annals of oncology: official journal of the European Society for Medical Oncology》 |2016年第6期|共7页
作者
Matulonis U. A.; Penson R. T.; Domchek S. M.; Kaufman B.; Shapira-Frommer R.; Audeh M. W.; Kaye S.; Molife L. R.; Gelmon K. A.; Robertson J. D.; Mann H.; Ho T. W.; Coleman R. L.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
olaparib; monotherapy; ovarian cancer; BRCA1; 2 mutation; pooled analysis;

机译：奥拉帕尼;单一疗法;卵巢癌;BRCA1;2突变;合并分析;

相似文献

外文文献
中文文献
专利

1. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety [J] . Matulonis U. A., Penson R. T., Domchek S. M., Annals of oncology: official journal of the European Society for Medical Oncology . 2016,第6期

机译：Olaparib单药治疗晚期复发性卵巢癌和生殖系BRCA1 / 2突变的患者：疗效和安全性的多研究分析
2. Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation [J] . Kaufman Bella, Shapira-Frommer Ronnie, Schmutzler Rita K., Journal of Clinical Oncology . 2015,第3期

机译：Olaparib单药治疗晚期癌症和生殖细胞BRCA1 / 2突变的患者
3. Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation [J] . Kaufman Bella, Shapira-Frommer Ronnie, Schmutzler Rita K., Journal of Clinical Oncology . 2015,第3期

机译：Olaparib单药治疗晚期癌症和生殖细胞BRCA1 / 2突变的患者
4. An Integrated Microfluidic Platform for Detecting BRCA1/BRCA2 Gene Mutation and Risk Assessment of Ovarian Cancer [C] . Yu-Hung Cheng, Chih-Hung Wang, Keng-Fu Hsu, International Conference on Solid-State Sensors, Actuators and Microsystems . 2021

机译：一种用于检测BRCA1 / BRCA2基因突变和卵巢癌风险评估的集成微流体平台
5. Dolo?anje Mutacij v Genih BRCA1/2 Iz citolo?kega Materiala Pri Raku jaj?nikov, Jajcevodov in Primarnem Peritonealnem Seroznem Karcinomu =BRCA1/2 mutation testing from cytological samples in patients with ovarian, tubal and primary peritoneal serous cancer [D] . Gornjec, Andreja. 2020

机译：从自我癌症中确定基因Krca1 / 2中的突变吗？
6. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy [O] . Susan M Domchek, Carol Aghajanian, Ronnie Shapira-Frommer, -1

机译：奥拉帕尼单药治疗晚期卵巢癌种系BRCA1 / 2突变携带者和三项或更多先前疗法的疗效和安全性
7. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. [O] . Domchek, Susan M, Aghajanian, Carol, Shapira-Frommer, Ronnie, 2016

机译：olaparib单药治疗对晚期卵巢癌和三种或更多种先前疗法的种系BRCa1 / 2突变携带者的疗效和安全性。

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety

摘要

著录项

相似文献

相关主题

期刊订阅